Ardelyx | ARDX - Cost Of Sales

Stock Price
6.59
Daily Change
0.07 1.07%
Monthly
22.04%
Yearly
15.82%
Q3 Forecast
6.47

Ardelyx reported $14.82M in Cost of Sales for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 466.77M
Cash and Equivalent USD 90.04M
Cost of Sales USD 14.82M
Current Assets USD 351.57M
Current Liabilities USD 81.72M
Debt USD 206.64M
Dividend Yield -6.39
EBIT USD -12.5M
EBITDA USD -11.87M
Employees 395
EPS Earnings Per Share USD -0.08
Equity Capital and Reserves USD 139.53M
Gross Profit on Sales USD 82.84M
Interest Expense on Debt USD 6.58M
Loan Capital USD 229.21M
Market Capitalization USD 1.52B
Net Income USD -19.08M
Operating Expenses USD 112.06M
Operating Profit USD -14.4M
Ordinary Share Capital USD 240.77M
Pre-Tax Profit USD -19.08M
Sales Revenues USD 97.66M
Selling and Administration Expenses USD 83.99M
Stock USD 22.28M
Trade Creditors USD 21.68M
Trade Debtors USD 62.55M

Cost Of Sales Change Date
Abbott USD 5.27B 834M Jun/2025
Amgen USD 3.01B 406M Jun/2025
Ardelyx USD 14.82M 3.44M Jun/2025
Corcept Therapeutics USD 3.43M 1.03M Jun/2025
Life Technologies USD 15.38M 15.38M Jun/2025
Sanofi EUR 2.99B 721M Jun/2025
TG Therapeutics USD 18.94M 3.4M Jun/2025
United Therapeutics USD 175.2M 102.3M Jun/2025